Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Soligenix axes lymphoma program after phase 3 setback
Soligenix has scrapped its cutaneous T-cell lymphoma program, leaving the biotech focused on another prospect and considering strategic alternatives.
Nick Paul Taylor
Jun 15, 2026 7:53am
Sanofi halts phase 3 autoimmune trial early over lackluster data
Jun 10, 2026 4:25am
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Jun 9, 2026 5:22am
Praxis pauses one of its seizure programs after phase 2 fail
Jun 2, 2026 5:23am
Agios’ next-gen PK drug fails ph. 2 blood cancer study
May 29, 2026 9:13am
Gilead scraps lead arthritis drug from $405M MiroBio buyout
May 29, 2026 7:18am
